Investigational drug · Phase 2
IMA401
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "IMA401"
First trial start
2023
Aug 9, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IMA401", any sponsor or status.
Conditions studied
As listed on its trial records.
- Refractory Cancer
- Recurrent Cancer
- Solid Tumor, Adult
- Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "IMA401" as an intervention, largest first.
- IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid TumorsRecruiting
Immatics Biotechnologies GmbHIndustry
NCT05958121 · 400 participants (planned) · Start Aug 9, 2023 · Primary completion Sep 2027
Drug: IMA402; IMA402 and checkpoint inhibitor and 4 more · For: Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult and 1 more
Sites: Heidelberg, Germany; Mannheim, Germany; Tübingen, Germany · 29 sites in all
- IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint InhibitorActive, not recruiting
Immatics Biotechnologies GmbHIndustry
NCT05359445 · 95 participants (planned) · Start May 19, 2022 · Primary completion Mar 18, 2026
Drug: IMA401 (Phase Ia); Pembrolizumab (Phase Ia) and 1 more · For: Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult and 1 more
Sites: Freiburg im Breisgau, Germany; Heidelberg, Germany; Tübingen, Germany · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- [Update on immunotherapy in head and neck cancer : New aspects from the ASCO annual meeting 2026].
Brand M, Hoffmann TK, Laban S · HNO 2026
- MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.
Wermke M, Ochsenreither S, Jaeger D, et al. · Nat Med 2026
Also in development for Refractory Cancer
- anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials
Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- Checkpoint InhibitorPhase 22 trials
EpicentRx, Inc. · Solid Tumor, Adult, Cancer, Neoplasms
- Monoclonal antibodyPhase 22 trials
Immunocore Ltd · Cancer, HLA-A*02:01-positive, Refractory Cancer
- HST-1011Phase 21 trial
HotSpot Therapeutics, Inc · Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
- IMA402Phase 21 trial
Immatics Biotechnologies GmbH · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.